ADC Therapeutics SA (NYSE:ADCT – Get Free Report) saw a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 2,710,000 shares, a decrease of 8.8% from the August 15th total of 2,970,000 shares. Based on an average daily volume of 651,900 shares, the short-interest ratio is currently 4.2 days.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on ADCT shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 price target on shares of ADC Therapeutics in a research report on Wednesday, August 7th. Cantor Fitzgerald started coverage on shares of ADC Therapeutics in a report on Thursday, May 30th. They issued an “overweight” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of ADC Therapeutics in a report on Thursday, August 8th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, ADC Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $9.00.
Check Out Our Latest Research Report on ADC Therapeutics
Insider Buying and Selling
Institutional Trading of ADC Therapeutics
Several large investors have recently modified their holdings of ADCT. Affinity Asset Advisors LLC bought a new stake in ADC Therapeutics during the second quarter valued at approximately $1,500,000. Bank of New York Mellon Corp purchased a new position in shares of ADC Therapeutics during the 2nd quarter worth $648,000. Sanibel Captiva Trust Company Inc. bought a new stake in shares of ADC Therapeutics during the 1st quarter valued at $462,000. Rhumbline Advisers purchased a new stake in shares of ADC Therapeutics in the 2nd quarter worth $272,000. Finally, XTX Topco Ltd increased its stake in shares of ADC Therapeutics by 129.0% in the 2nd quarter. XTX Topco Ltd now owns 56,863 shares of the company’s stock worth $180,000 after purchasing an additional 32,034 shares in the last quarter. Institutional investors own 41.10% of the company’s stock.
ADC Therapeutics Stock Down 1.1 %
ADCT traded down $0.04 during midday trading on Wednesday, hitting $3.09. 178,309 shares of the company traded hands, compared to its average volume of 684,891. The company’s 50-day moving average is $3.14 and its 200 day moving average is $3.69. The firm has a market capitalization of $255.37 million, a PE ratio of -1.12 and a beta of 1.58. ADC Therapeutics has a 52 week low of $0.36 and a 52 week high of $6.04.
ADC Therapeutics (NYSE:ADCT – Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.06. The company had revenue of $17.41 million during the quarter, compared to analysts’ expectations of $19.06 million. During the same quarter in the prior year, the business posted ($0.58) EPS. On average, sell-side analysts predict that ADC Therapeutics will post -1.69 earnings per share for the current fiscal year.
About ADC Therapeutics
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Read More
- Five stocks we like better than ADC Therapeutics
- Canada Bond Market Holiday: How to Invest and Trade
- How Much Can You Make in Stocks in One Month?
- Compound Interest and Why It Matters When Investing
- This Is the Top Large-Cap Stock Insiders Are Buying
- Golden Cross Stocks: Pattern, Examples and Charts
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.